OpenLB
Open Library of Bioscience
Advanced Search
Experimental and therapeutic medicine
May, 2023;25 (5): 209.

Drug‑resistant : From molecular mechanisms to potential therapeutics (Review).

Hao-Jia Wu, Zhi-Gang Xiao, Xiao-Juan Lv, Hai-Tang Huang, Chu Liao, Chen-Yang Hui, Yue Xu, Heng-Fei Li
Author Information
  1. Hao-Jia Wu: Clinical College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, P.R. China.
  2. Zhi-Gang Xiao: Department of Orthopedics, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei 430061, P.R. China.
  3. Xiao-Juan Lv: Department of Hepatology, Hubei Key Laboratory of The Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei 430061, P.R. China.
  4. Hai-Tang Huang: Department of Hepatology, Hubei Key Laboratory of The Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei 430061, P.R. China.
  5. Chu Liao: Department of Hepatology, Hubei Key Laboratory of The Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei 430061, P.R. China.
  6. Chen-Yang Hui: Department of Hepatology, Hubei Key Laboratory of The Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei 430061, P.R. China.
  7. Yue Xu: Clinical College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, P.R. China.
  8. Heng-Fei Li: Department of Hepatology, Hubei Key Laboratory of The Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei 430061, P.R. China.
PMID: 37090073 DOI: 10.3892/etm.2023.11908

Abstract

Bacterial drug resistance is increasingly becoming an important problem that needs to be solved urgently in modern clinical practices. Infection caused by is a serious threat to the life and health of patients. The drug resistance rate of strains is increasing, thus research on the drug resistance of has also seen an increase. When patients are infected with drug-resistant , the availability of suitable antibiotics commonly used in clinical practices is becoming increasingly limited and the prognosis of patients is worsening. Studying the molecular mechanism of the drug resistance of is fundamental to solving the problem of drug-resistant and potentially other 'super bacteria'. Drug resistance mechanisms primarily include enzymes, membrane proteins, efflux pumps and beneficial mutations. Research on the underlying mechanisms provides a theoretical basis for the use and development of antibiotics and the development of novel treatment methods.

Keywords

Acinetobacter baumannii antibiotics drug resistance treatment

References

  1. Curr Res Transl Med. 2019 Nov;67(4):115-122 [PMID: 31155436]
  2. Clin Lab. 2020 Mar 1;66(3): [PMID: 32162864]
  3. Front Med (Lausanne). 2022 Mar 24;9:793615 [PMID: 35402433]
  4. Pathogens. 2021 Mar 31;10(4): [PMID: 33807410]
  5. Microb Genom. 2019 Oct;5(10): [PMID: 31599224]
  6. Nature. 2022 Jan;601(7894):606-611 [PMID: 34987225]
  7. Antibiotics (Basel). 2020 Apr 23;9(4): [PMID: 32340386]
  8. J Appl Microbiol. 2021 Dec;131(6):2715-2738 [PMID: 33971055]
  9. J Glob Antimicrob Resist. 2020 Mar;20:204-208 [PMID: 31112806]
  10. Clin Microbiol Rev. 2020 Nov 11;34(1): [PMID: 33177185]
  11. Rev Soc Bras Med Trop. 2021 Jan 29;54:e05992020 [PMID: 33533819]
  12. mBio. 2019 Jul 16;10(4): [PMID: 31311879]
  13. Antimicrob Agents Chemother. 2020 Apr 21;64(5): [PMID: 32071042]
  14. Front Cell Infect Microbiol. 2020 May 29;10:253 [PMID: 32547965]
  15. Front Microbiol. 2021 Oct 05;12:725194 [PMID: 34675899]
  16. BMC Complement Med Ther. 2020 Mar 19;20(1):92 [PMID: 32192484]
  17. Lancet Infect Dis. 2022 Jan;22(1):e28-e34 [PMID: 34246322]
  18. Toxins (Basel). 2019 Apr 10;11(4): [PMID: 30974767]
  19. J Cell Physiol. 2022 Apr;237(4):2045-2063 [PMID: 35083758]
  20. Vaccines (Basel). 2021 Jun 01;9(6): [PMID: 34205838]
  21. J Infect Chemother. 2017 Feb;23(2):74-79 [PMID: 27889248]
  22. Infect Drug Resist. 2021 Jan 06;14:33-48 [PMID: 33442274]
  23. Antibiotics (Basel). 2020 Mar 12;9(3): [PMID: 32178356]
  24. Phytomedicine. 2012 Feb 15;19(3-4):236-8 [PMID: 22240078]
  25. BMC Infect Dis. 2021 Aug 20;21(1):841 [PMID: 34416851]
  26. Eur J Clin Microbiol Infect Dis. 2022 Jul;41(7):1003-1022 [PMID: 33403565]
  27. Rev Esp Quimioter. 2010 Mar;23(1):12-9 [PMID: 20232019]
  28. Pathogens. 2020 Dec 19;9(12): [PMID: 33352688]
  29. Microbes Infect. 2021 May-Jun;23(4-5):104795 [PMID: 33567337]
  30. J Intensive Care. 2020 Jan 28;8:13 [PMID: 32015881]
  31. Ann Clin Microbiol Antimicrob. 2019 Jul 2;18(1):19 [PMID: 31266519]
  32. Sci Rep. 2020 Dec 15;10(1):21975 [PMID: 33319862]
  33. Clin Lab. 2019 Jul 1;65(7): [PMID: 31307186]
  34. Microbiol Res. 2022 Jul;260:127032 [PMID: 35483311]
  35. J Hosp Infect. 2020 Jan;104(1):4-11 [PMID: 31589900]
  36. Int J Microbiol. 2021 Oct 7;2021:9923816 [PMID: 34659419]
  37. J Appl Microbiol. 2019 Oct;127(4):1038-1047 [PMID: 31319012]
  38. Infect Prev Pract. 2020 Jul 19;2(3):100077 [PMID: 34368717]
  39. Front Microbiol. 2016 Feb 18;7:174 [PMID: 26925046]
  40. Int J Microbiol. 2021 Mar 17;2021:5565537 [PMID: 33815505]
  41. Int J Mol Sci. 2020 Jul 31;21(15): [PMID: 32752093]
  42. Microb Drug Resist. 2019 Sep;25(7):997-1002 [PMID: 30964377]
  43. J Ethnopharmacol. 2021 Jan 10;264:113266 [PMID: 32810621]
  44. Infect Drug Resist. 2018 Jun 06;11:861-872 [PMID: 29922077]
  45. Infect Dis Ther. 2022 Apr;11(2):683-694 [PMID: 35175509]
  46. BMC Complement Altern Med. 2018 Mar 20;18(1):96 [PMID: 29554903]
  47. Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1009-1019 [PMID: 29524060]
  48. Ann Lab Med. 2018 May;38(3):266-270 [PMID: 29401563]
  49. PLoS One. 2018 Aug 22;13(8):e0201961 [PMID: 30133491]
  50. J Antimicrob Chemother. 2019 Apr 1;74(4):944-952 [PMID: 30629184]
  51. Microbiol Spectr. 2022 Jun 29;10(3):e0054222 [PMID: 35647655]
  52. ACS Infect Dis. 2018 Mar 9;4(3):325-336 [PMID: 29144724]
  53. J Glob Antimicrob Resist. 2020 Sep;22:219-225 [PMID: 32084603]
  54. Infect Drug Resist. 2021 Nov 05;14:4657-4666 [PMID: 34764660]
  55. Antimicrob Agents Chemother. 2020 May 21;64(6): [PMID: 32152086]
  56. World J Microbiol Biotechnol. 2018 Dec 3;34(12):189 [PMID: 30511216]
  57. Front Microbiol. 2020 Oct 06;11:589234 [PMID: 33123117]
  58. Sci Rep. 2021 Oct 11;11(1):20136 [PMID: 34635692]
  59. Front Cell Infect Microbiol. 2021 Mar 25;11:660431 [PMID: 33842399]
  60. Microb Pathog. 2021 Sep;158:105063 [PMID: 34166729]
  61. J Biomed Sci. 2020 Jan 18;27(1):26 [PMID: 31954394]
  62. Res Microbiol. 2020 Apr - Jun;171(3-4):128-133 [PMID: 31988011]
  63. Planta Med. 2023 Feb;89(2):168-182 [PMID: 35995069]
  64. Virol Sin. 2019 Aug;34(4):347-357 [PMID: 31093881]
  65. mBio. 2021 Jun 29;12(3):e0103121 [PMID: 34044590]
  66. Infect Dis (Lond). 2019 Jul;51(7):493-501 [PMID: 31081415]
  67. Nat Commun. 2019 Aug 9;10(1):3617 [PMID: 31399590]
  68. Microorganisms. 2020 Jun 21;8(6): [PMID: 32575913]
  69. J Biosci. 2021;46: [PMID: 34475315]
  70. J Mol Biol. 2019 Aug 23;431(18):3472-3500 [PMID: 30959050]
  71. Front Pharmacol. 2022 May 11;13:890955 [PMID: 35645826]
  72. Microbiol Spectr. 2018 Jun;6(3): [PMID: 30101740]
  73. Pathogens. 2021 Mar 19;10(3): [PMID: 33808905]
  74. Antibiotics (Basel). 2021 May 13;10(5): [PMID: 34068158]
  75. Jpn J Infect Dis. 2021 Nov 22;74(6):499-506 [PMID: 33642430]
  76. Emerg Microbes Infect. 2020 Dec;9(1):639-650 [PMID: 32192413]
  77. Microbiol Spectr. 2021 Oct 31;9(2):e0101021 [PMID: 34523993]
  78. Microorganisms. 2021 Nov 18;9(11): [PMID: 34835509]
  79. Ann Clin Microbiol Antimicrob. 2019 Jan 3;18(1):1 [PMID: 30606201]
  80. Nat Rev Microbiol. 2018 Feb;16(2):91-102 [PMID: 29249812]
  81. J Infect Public Health. 2019 Nov - Dec;12(6):890-896 [PMID: 31230951]
  82. Microb Pathog. 2022 Dec;173(Pt A):105874 [PMID: 36356792]
  83. Infect Drug Resist. 2019 May 13;12:1171-1180 [PMID: 31190906]
  84. J Infect Public Health. 2021 Nov;14(11):1679-1685 [PMID: 34627065]
  85. J Antimicrob Chemother. 2020 May 1;75(5):1135-1139 [PMID: 32049277]
  86. Antimicrob Agents Chemother. 2018 Dec 21;63(1): [PMID: 30323035]
  87. Antibiotics (Basel). 2022 May 04;11(5): [PMID: 35625263]
  88. PLoS One. 2021 Feb 22;16(2):e0247418 [PMID: 33617547]
  89. Bioinformatics. 2013 Sep 1;29(17):2122-8 [PMID: 23782617]
  90. Antibiotics (Basel). 2021 Mar 09;10(3): [PMID: 33803296]
  91. Antibiotics (Basel). 2020 Nov 17;9(11): [PMID: 33212840]
  92. Pharmacotherapy. 2020 Dec;40(12):1228-1247 [PMID: 33068441]
  93. Mol Biol Rep. 2021 Oct;48(10):6987-6998 [PMID: 34460060]
  94. BMC Infect Dis. 2021 Aug 9;21(1):782 [PMID: 34372787]
  95. Clin Microbiol Rev. 2019 Jan 30;32(2): [PMID: 30700432]
  96. Adv Exp Med Biol. 2019;1145:55-71 [PMID: 31364071]
  97. Clin Microbiol Rev. 1996 Apr;9(2):148-65 [PMID: 8964033]
  98. Clin Lab. 2021 Aug 1;67(8): [PMID: 34383423]
  99. ACS Infect Dis. 2020 Jan 10;6(1):91-99 [PMID: 31646866]
  100. Int J Antimicrob Agents. 2020 Apr;55(4):105918 [PMID: 32007593]
  101. PLoS One. 2021 Dec 17;16(12):e0259915 [PMID: 34919563]
  102. Biomolecules. 2020 May 06;10(5): [PMID: 32384624]
  103. Drugs. 2019 Feb;79(3):271-289 [PMID: 30712199]
  104. Pharmacol Rev. 2021 Apr;73(2):679-728 [PMID: 33627412]
  105. Front Mol Biosci. 2018 Feb 23;5:16 [PMID: 29527530]
  106. Antimicrob Agents Chemother. 2018 Aug 27;62(9): [PMID: 29941648]
Journal Article Review
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0resistancedrugpatientsantibioticsmechanismsincreasinglybecomingproblemclinicalpracticesdrug-resistantmoleculardevelopmenttreatmentBacterialimportantneedssolvedurgentlymodernInfectioncausedseriousthreatlifehealthratestrainsincreasingthusresearchalsoseenincreaseinfectedavailabilitysuitablecommonlyusedlimitedprognosisworseningStudyingmechanismfundamentalsolvingpotentially'superbacteria'DrugprimarilyincludeenzymesmembraneproteinseffluxpumpsbeneficialmutationsResearchunderlyingprovidestheoreticalbasisusenovelmethodsDrug‑resistant:potentialtherapeuticsReviewAcinetobacterbaumannii

Similar Articles

Cited By